
Barbora BrodskÃ;

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4168935/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>NPM1</i> and <i>DNMT3A</i> mutations are associated with distinct blast immunophenotype in acute myeloid leukemia. Oncolmmunology, 2022, 11, 2073050.	4.6	1
2	Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells. Applied Sciences (Switzerland), 2021, 11, 460.	2.5	3
3	Group I p21-activated kinases in leukemia cell adhesion to fibronectin. Cell Adhesion and Migration, 2021, 15, 18-36.	2.7	7
4	NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization. Scientific Reports, 2021, 11, 1084.	3.3	7
5	AML-Related NPM Mutations Drive p53 Delocalization into the Cytoplasm with Possible Impact on p53-Dependent Stress Response. Cancers, 2021, 13, 3266.	3.7	6
6	Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib. International Journal of Oncology, 2020, 58, 238-250.	3.3	14
7	High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. International Journal of Molecular Sciences, 2019, 20, 2823.	4.1	39
8	Nucleophosmin in leukemia: Consequences of anchor loss. International Journal of Biochemistry and Cell Biology, 2019, 111, 52-62.	2.8	11
9	PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions. Scientific Reports, 2019, 9, 17171.	3.3	15
10	Lifetime-based photoconversion of EGFP as a tool for FLIM. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 266-277.	2.4	9
11	Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin. PLoS ONE, 2018, 13, e0204290.	2.5	15
12	AML-associated mutation of nucleophosmin compromises its interaction with nucleolin. International Journal of Biochemistry and Cell Biology, 2018, 103, 65-73.	2.8	12
13	Monitoring of nucleophosmin oligomerization in live cells. Methods and Applications in Fluorescence, 2018, 6, 035016.	2.3	13
14	Localization of AML-related nucleophosmin mutant depends on its subtype and is highly affected by its interaction with wild-type NPM. PLoS ONE, 2017, 12, e0175175.	2.5	22
15	Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility. Cancer Immunology Research, 2016, 4, 815-819.	3.4	8
16	Lowâ€Dose Actinomycinâ€D Induces Redistribution of Wildâ€Type and Mutated Nucleophosmin Followed by Cell Death in Leukemic Cells. Journal of Cellular Biochemistry, 2016, 117, 1319-1329.	2.6	22
17	Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0127637.	2.5	26
18	Decitabine and SAHA-Induced Apoptosis Is Accompanied by Survivin Downregulation and Potentiated by ATRA in p53-Deficient Cells. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-13.	4.0	7

#	Article	IF	CITATIONS
19	Combined Treatment with Low Concentrations of Decitabine and SAHA Causes Cell Death in Leukemic Cell Lines but Not in Normal Peripheral Blood Lymphocytes. BioMed Research International, 2013, 2013, 1-11.	1.9	12
20	Generation of Reactive Oxygen Species during Apoptosis Induced by DNA-Damaging Agents and/or Histone Deacetylase Inhibitors. Oxidative Medicine and Cellular Longevity, 2011, 2011, 1-7.	4.0	54
21	Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. Molecular and Cellular Biochemistry, 2011, 350, 71-80.	3.1	19
22	Doseâ€dependent effects of the caspase inhibitor Qâ€VDâ€OPh on different apoptosisâ€related processes. Journal of Cellular Biochemistry, 2011, 112, 3334-3342.	2.6	37
23	Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. Journal of Cellular Biochemistry, 2010, 109, 184-195.	2.6	17
24	Variations in câ€Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimELâ€mediated cell death. Cell Biochemistry and Function, 2009, 27, 167-175.	2.9	5
25	BimELâ€dependent apoptosis induced in peripheral blood lymphocytes with <i>n</i> â€butyric acid is moderated by variation in expression of câ€myc and p21(WAF1). Cell Biochemistry and Function, 2008, 26, 509-521.	2.9	4
26	Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anti-Cancer Drugs, 2007, 18, 763-772.	1.4	18